John Castellani News
-
President Barack Obama raised $738.5 million for his successful re-election effort, almost as much as the record $745 million he brought in four years earlier, Federal Election Commission filings show.
-
John Castellani , head of the Business Roundtable, will become the U.S. drug industry’s top lobbyist.
-
Drugmakers may push to boost U.S. government spending on prescription drugs even as the U.S. Congress seeks to reduce health-care spending, according to internal documents from the industry’s top lobbying group.
-
The U.S. risks losing thousands of research jobs as countries led by Singapore, Ireland and South Africa boost incentives to woo drugmakers, said John Castellani, head of a pharmaceutical industry lobbying group.
-
Carlyle Group co-founder David Rubenstein and his wife, Alice, recently donated a 5,000-pipe organ to the Kennedy Center.
-
MF Global Holdings Ltd. argued in a December 2010 letter to regulators that futures brokers didn’t need tighter restrictions on how they invest client funds. Ten months later, as MF Global filed for bankruptcy, about $1.6 billion in customer accounts was missing.
-
President Barack Obama’s budget plan would trim spending on federal health programs at the expense of drugmakers, hospitals and nursing homes while seeking nearly $1 billion for carrying out the 2010 health-care law.
-
When House Republicans took power in 1995 determined to cut spending in a battle that shut down the U.S. government, then-House Speaker Newt Gingrich was persuaded to spare the National Institutes of Health.
-
Pfizer Inc. and Merck & Co. are being pulled into an expanding congressional investigation about the agreement drugmakers reached with the Obama administration to support the Democrats’ overhaul of the U.S. health-care system, according to three people familiar with the talks.
-
In a year of tumult in U.S. politics in which control of Congress appears up for grabs, the result for business leaders is a climate lacking the certainty they crave for decision-making.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page